V-161, a novel compound targeting the Na+ -V-ATPase enzyme in vancomycin-resistant Enterococcus faecium (VRE), significantly reduces bacterial growth and colonization.
MEDICLIN presents preliminary figures for the 2024 financial year – Biotech Investments
EQS-News: MEDICLIN AG / Key word(s): Preliminary Results MEDICLIN presents preliminary figures for the 2024 financial year 27.02.2025 / 13:03 CET/CEST The issuer is solely